These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 30588905

  • 1. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM.
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
    Med Lett Drugs Ther; 2016 Jun 06; 58(1496):74-5. PubMed ID: 27249096
    [No Abstract] [Full Text] [Related]

  • 4. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L, Norton JC, Chi-Burris K, Demos G.
    CNS Spectr; 2018 Jun 06; 23(3):228-238. PubMed ID: 29098976
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH.
    Neuropsychopharmacology; 2010 Mar 06; 35(4):881-92. PubMed ID: 19907417
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pimavanserin for Parkinson Disease Psychosis.
    Mohanty D, Sarai S, Naik S, Lippmann S.
    Prim Care Companion CNS Disord; 2019 Apr 25; 21(2):. PubMed ID: 31050230
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I, Ferreira JJ.
    Expert Opin Pharmacother; 2016 Oct 25; 17(15):2115-24. PubMed ID: 27609312
    [Abstract] [Full Text] [Related]

  • 15. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
    Isaacson SH, Ballard CG, Kreitzman DL, Coate B, Norton JC, Fernandez HH, Ilic TV, Azulay JP, Ferreira JJ, Abler V, Stankovic S, 015 Study Group.
    Parkinsonism Relat Disord; 2021 Jun 25; 87():25-31. PubMed ID: 33933853
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
    Wilby KJ, Johnson EG, Johnson HE, Ensom MHH.
    Ann Pharmacother; 2017 Aug 25; 51(8):682-695. PubMed ID: 28385039
    [Abstract] [Full Text] [Related]

  • 19. Psychiatric commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
    Citrome L.
    CNS Spectr; 2018 Dec 25; 23(6):355-357. PubMed ID: 30588903
    [Abstract] [Full Text] [Related]

  • 20. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH.
    Expert Opin Pharmacother; 2013 Oct 25; 14(14):1969-75. PubMed ID: 24016069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.